-+ 0.00%
-+ 0.00%
-+ 0.00%

TAKKT (XTRA:TTK) Stock Price Sinks As Q3 Results Expose Margin Strain

Simply Wall St·10/30/2026 20:35:16
Listen to the news

TAKKT stock closed at €2.50 on 30 October, down sharply over the past month, just as investors absorbed a Q3 2026 report that put profitability back under the microscope. The headline is simple and uncomfortable. The business posted a quarterly net loss of €18.1m on €232.2m in revenue, with basic earnings per share of €0.28 in the red.

Short term traders are reacting to red ink. Longer term holders are weighing something bigger: a multi year stretch of trailing losses and a cyberattack that now sits directly on top of already thin margins in a capital intensive B2B distribution model.

Concerned that TAKKT’s recent losses and cyberattack highlight deeper balance sheet pressure in a low margin distribution model. Compare this setup against a list of solid balance sheet and fundamentals stocks (202 results) for ideas with sturdier financial foundations.

Q3 2026 Earnings Summary

  • Revenue (Q3 2026 vs Q3 2025): €232.2m vs. €244.8m (decline of about 5%)
  • Net Income/Loss (Q3 2026 vs Q3 2025): loss of €18.1m vs. profit of €1.2m (a swing deeper into the red of more than 15 times)
  • Basic EPS (Q3 2026 vs Q3 2025): loss of €0.28 per share vs. earnings of €0.02 per share (moved from a small profit to a clear loss)
  • Adjusted EBITDA Margin (Q3 2026 vs Q3 2025): 3.0% vs. 4.3% (compression of 1.3 percentage points, indicating weaker underlying profitability)

Tired of scrolling through dense reports and trying to piece together what TAKKT’s latest numbers really mean for the business? Get a complete visual overview of the company’s balance sheet strength, liabilities, and cash position in an intuitive dashboard via our company report for TAKKT.

XTRA:TTK Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026
XTRA:TTK Trailing 12-Month Revenue & Expenses Breakdown as at Oct 2026

TAKKT margin story vs. transformation milestones

Bulls argue TAKKT’s overhaul should steadily rebuild earnings quality and visibility.

"Expansion of AI driven process automation in ordering, catalog production and translations, together with the competence center in Hungary and FTE reductions, is set to structurally lower operating costs and lift net margins over time."

The latest quarter shows some groundwork, not yet the payoff. Adjusted EBITDA margin sits at 3.0%, weaker than last year, and free cash flow for the first nine months is still negative at €12.7m. Foodservices only just moved to a slim positive contribution. Cost measures help, but the margin thesis has not been proven.

Cyber hit and impairments test TAKKT risk view

The bear case centers on whether operational setbacks and write downs overwhelm any efficiency gains.

"Potential large scale impairments in the U.S. businesses, particularly in FoodService and possibly D2G where management already sees a significantly high multimillion euro risk and no remaining headroom, would signal structurally lower profitability than previously assumed."

Recent figures give this concern real weight. Management has already booked an impairment in Foodservices after updating multi year plans, and group EBITDA remains depressed. The cyberattack now restricts processing capacity to roughly 10% of normal, raises the chance of weaker Q4 revenue conversion, and increases the risk of finishing the year below guidance ranges.

One Narrative disagrees with today's price. → See where this Narrative says TAKKT should trade.

Hunt For Mispriced Earnings Power

TAKKT’s latest quarter shows how quickly sentiment can change when profitability and resilience face scrutiny. The real opportunity could be identifying stocks that appear undervalued before investors fully recognize their earnings power.

  • Company 1 - 38% below our estimate - redirects capital toward higher margin infrastructure and industrial projects while shrinking weaker housing exposure.
  • Company 2 - 37% below our estimate - replaces older blast furnaces with electric arc capacity and reshapes product mix toward higher margin rail and storage systems contracts.
  • Company 3 - 30% below our estimate - ramps new high value drug development and manufacturing services backed by a sizeable outsourcing-focused pharma order backlog.

Three companies from the same screener. Open all 201 potentially undervalued companies →